Avadel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Avadel Pharmaceuticals has a total shareholder equity of $78.4M and total debt of $34.3M, which brings its debt-to-equity ratio to 43.8%. Its total assets and total liabilities are $167.9M and $89.5M respectively.
Key information
43.8%
Debt to equity ratio
US$34.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$88.79m |
| Equity | US$78.38m |
| Total liabilities | US$89.52m |
| Total assets | US$167.90m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AWK's short term assets ($136.0M) exceed its short term liabilities ($47.8M).
Long Term Liabilities: AWK's short term assets ($136.0M) exceed its long term liabilities ($41.7M).
Debt to Equity History and Analysis
Debt Level: AWK has more cash than its total debt.
Reducing Debt: AWK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AWK has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if AWK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.